Clinical Trial

TaVNS for Acute Intracerebral Hemorrhage

Study acronym: TAVANS-ICH
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with acute intracerebral hemorrhage (ICH). The taVNS intervention will be delivered using the BS-TVNS800-1 transcutaneous electrical stimulation therapy device (KERFUN, Shanxi, China). A total of 186 patients will be randomly assigned in a 1:1 ratio to either the taVNS group or the sham-taVNS group. The primary outcome is the relative volume of perihematoma edema assessed on day 10-14 after randomization. Adverse events associated with taVNS therapy will be systematically evaluated to assess its safety profile.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-07; most recent amendment 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2025-09-15
Trial Details
NCT Number NCT06918964
Lead Sponsor Beijing Tiantan Hospital
Conditions Intracerebral Hemorrhage
Enrollment 186 participants
Start Date 2025-09-15
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-15